Abstract
Background: This study identifies the Hedgehog pathway coreceptor CDO as a new molecular target in rhabdomyosarcoma and initiates preclinical drug development of the first experimental anti-CDO compound, a novel small molecule with high therapeutic potential.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
